semaglutide and ketosis Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults Beyond GLP-1 Agonists: An Adaptive

Results showed semaglutide reduced the risk of major adverse cardiac events by 26 percent compared to placebo, including fewer heart attacks and strokes

However, long-term registry studies, cardiovascular outcome trials, and recent meta-analyses provide a more reassuring picture

Rapid weight loss can trigger telogen effluvium (diffuse hair shedding) 23 months into therapy, independent of any direct drug effect

[12] Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) indicate that serious hepatic adverse events with semaglutide are rare, though such spontaneous reporting systems have inherent limitations and cannot establish true incidence or definitive causality

But they contain different active ingredients, work through different mechanisms, and as the landmark 2025 SURMOUNT-5 trial revealed they do not produce equal results

After many studies, results showed that Tirzepatide stimulates more weight reduction than Semaglutide